AusgewÄHLTE Publikationen


Erb K, Pechstein B, Schueler A, Engel J, Hermann R.
Pituitary and gonadal endocrine effects and pharmacokinetics of the novel luteinizing hormone-releasing hormone
antagonist teverelix in healthy men – a first-dose-in-humans study.
Clin Pharmacol Ther. 2000 Jun;67(6):660-9.


Erb K, Klipping C, Duijkers I, Pechstein B, Schueler A, Hermann R.
Pharmacodynamic effects and plasma pharmacokinetics of single doses of cetrorelix acetate in
healthy premenopausal women.
Fertil Steril. 2001 Feb;75(2):316-23.


Erb K, Junge K, Pechstein B, Schneider E, Derendorf H, Hermann R.
Novel formulations of cetrorelix acetate in healthy men: pharmacodynamic effects and
noncompartmental pharmacokinetics.
J Clin Pharmacol. 2002 Sep;42(9):995-1001.


Skarke C, Jarrar M, Erb K, Schmidt H, Geisslinger G, Lötsch J.
Respiratory and miotic effects of morphine in healthy volunteers when P-glycoprotein is blocked by quinidine.
Clin Pharmacol Ther. 2003 Oct;74(4):303-11.


Jetter A, Kinzig-Schippers M, Illauer M, Hermann R, Erb K, Borlak J, Wolf H, Smith G, Cascorbi I, Sörgel F, Fuhr U.
Phenotyping of N-acetyltransferase type 2 by caffeine from uncontrolled dietary exposure.
Eur J Clin Pharmacol. 2004 Mar;60(1):17-21.


Cnota PJ, Nowak H, Tagarro I, Erb K, Schürer M, Schulz HU, Maus J.
Tramadol SR Formulations : Pharmacokinetic Comparison of a Multiple-Units Dose (Capsule) versus
a Single-Unit Dose (Tablet).
Clin Drug Investig. 2005;25(7):435-43.


Hermann R, Borlak J, Munzel U, Niebch G, Fuhr U, Maus J, Erb K.
The role of Gilbert's syndrome and frequent NAT2 slow acetylation polymorphisms in
the pharmacokinetics of retigabine.
Pharmacogenomics J. 2006 May-Jun;6(3):211-9.